And we were talking about the problem that there were not medical--pharmaceutical countermeasures and how do we create a market incentive where there is no natural market incentive for pharmaceutical companies to devote research to this.
Lieberman highlights the lack of market incentives for pharmaceutical research after 9/11.
Share
More from Joe Lieberman
I appreciate the leadership that the Committee is showing, because this really is a threat to our country.
I think this is a unique moment in history, where the American people are so fed up with the two parties and the two logical probable candidates that they're going to welcome a bipartisan unity third choice on the ballot.
Other voices in this conversation
